A Phase III, Multicenter, Randomized, Open-label Study of Atezolizumab(anti-PD-L1 antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence after Surgical Resection or Ablation
A Study of Atezolizumab Plus Bevacizumab Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
Sponsor: Hoffmann-La Roche
Enrolling: Male and Female Patients
IRB Number: AAAS7352
U.S. Govt. ID: NCT04102098
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the effects, good or bad, of atezolizumab plus bevacizumab versus observation (not receiving any treatment) on patients with completely resected (surgically removed) or ablated (removed using heat) hepatocellular carcinoma (the most common type of liver cancer) who are at high risk for disease recurrence. Atezolizumab is an antibody (a protein similar to the ones produced by the body's immune system) that blocks the programmed death-ligand 1 (PD-L1) pathway. The PD L1 pathway is involved in regulating the body's natural immune response, but tumors can take advantage of this regulation to partially resist or evade the immune system. By blocking the PD-L1 pathway, atezolizumab may help the immune system stop or reverse the growth of tumors. Bevacizumab is an antibody that slows the growth of new blood vessels and may help the body stop the growth of tumors.
This study is closed
Gulam Manji, MD, PhD
Do You Qualify?
Have you been told may be at risk for recurrence of your liver cancer? Yes No
Are you 18 years of age or older? Yes No
Are you willing to come to the clinic for extra tests and visits? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator